AGN does not prevent secondary brain injury, protect the heart muscle and stop sudden cardiac arrest in stroke and heart attacks. 25 million should be a 100 million market cap on safety clearance like peers except we are much bigger with a Swisse army knife drug. Got a lot to rerate and 50 cent all time high will be tested
“At a market capitalization of just $19m NYR appears significantly undervalued relative to its industry peers. A key comparison is Argenica Therapeutics Limited (ASX: AGN), which is at a comparable stage of clinical development yet trades at approximately $95m – five times NYR’s valuation. This valuation gap suggests that the market has not fully recognized NYR’s potential.”
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)